Funding Opportunities

NIH Funding Opportunities

Notice of Correction to Application Package for PA-14-037 "Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03)"
Notice NOT-DA-14-051 from the NIH Guide for Grants and Contracts
Mon, 20 Oct 2014 02:38:26 EST

Notice of Correction to the Funding Opportunity Description in PA-15-003 "Epidemiology of Drug Abuse (R01)"
Notice NOT-DA-14-053 from the NIH Guide for Grants and Contracts
Wed, 22 Oct 2014 11:03:58 EST

Notice of Updates to the National Robotics Initiative (NRI)
Notice NOT-EB-14-008 from the NIH Guide for Grants and Contracts
Thu, 23 Oct 2014 03:44:43 EST

Notice of Technical Assistance Webinar for RFA-ES-14-002 "Children's Environmental Health and Disease Prevention Research Centers (P50)"
Notice NOT-ES-15-003 from the NIH Guide for Grants and Contracts
Fri, 24 Oct 2014 03:27:11 EST

Notice of Participation of NIMHD in PA-13-119 "Mechanisms, Models, Measurement, and Management in Pain Research (R21)"
Notice NOT-MD-14-008 from the NIH Guide for Grants and Contracts
Mon, 20 Oct 2014 02:52:10 EST

Notice of Correction Regarding Institution Eligibility Requirements for RFA-NS-14-013 "NINDS Institutional Center Core Grants to Support Neuroscience Research (P30)"
Notice NOT-NS-15-001 from the NIH Guide for Grants and Contracts
Wed, 22 Oct 2014 08:55:16 EST

Notice to Extend PAR-12-032 "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Etiology, Diagnosis, Pathophysiology, and Treatment (R01)" by an Additional Funding Cycle
Notice NOT-OD-15-006 from the NIH Guide for Grants and Contracts
Thu, 23 Oct 2014 11:34:45 EST

Notice to Extend PAR-12-033 "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Etiology, Diagnosis, Pathophysiology, and Treatment (R21)" by an Additional Funding Cycle
Notice NOT-OD-15-007 from the NIH Guide for Grants and Contracts
Wed, 22 Oct 2014 04:12:28 EST

Notice of Clarification of 4-Year Limit of Postdoctoral Research Eligibility for K99 Applicants for PA-14-042 NIH Pathway to Independence Award (Parent K99/R00)
Notice NOT-OD-15-013 from the NIH Guide for Grants and Contracts
Thu, 23 Oct 2014 12:08:01 EST

Notice of Revised NIH Definition of Clinical Trial
Notice NOT-OD-15-015 from the NIH Guide for Grants and Contracts
Thu, 23 Oct 2014 03:16:12 EST

Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01)
Funding Opportunity RFA-DK-14-023 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support innovative research in humans to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. Proposed projects must involve human subjects with HIV infection or materials or data from HIV-infected individuals. Proposed projects must also be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK).
Mon, 20 Oct 2014 12:30:38 EST

Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR) (R43/R44)
Funding Opportunity RFA-EB-15-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving one or more health disparity populations during Phase I and Phase II.
Fri, 24 Oct 2014 03:10:07 EST

Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)
Funding Opportunity RFA-FD-15-001 from the NIH Guide for Grants and Contracts. The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application's Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a rare disease or condition and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
Mon, 20 Oct 2014 03:30:12 EST

Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)
Funding Opportunity RFA-HD-15-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue addressing two critical scientific questions on the clinical course of perinatally acquired HIV infection in adolescents and the oral and systemic health consequences of in utero and infant exposure to antiretroviral chemotherapy in representative cohorts of children in the United States. The CC is responsible for maintaining the Scientific Leadership Group (SLG) through performance-based subcontracts. The SLG should continue to have scientific specialty working groups to reflect the different disciplines required to successfully implement the protocols and substudies.
Thu, 23 Oct 2014 09:42:13 EST

Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) (U01)
Funding Opportunity RFA-HD-15-029 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to continue support for the Pediatric HIV/AIDS Cohort Study (PHACS) which addresses critical scientific questions on the clinical course of perinatally acquired HIV infection in adolescents and young adults and the oral and systemic health consequences of in utero and infant exposure to antiretroviral chemotherapy in representative cohorts of children in the United States. The data and operations center (DOC) will continue to coordinate clinical site activities (including community advisory board participation and activities), to provide methodological and analytical support, and to manage the database, including reconciliation with collaborating databases
Thu, 23 Oct 2014 10:41:28 EST

NIH Director's Early Independence Awards (DP5)
Funding Opportunity RFA-RM-14-004 from the NIH Guide for Grants and Contracts. The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.
Tue, 21 Oct 2014 12:58:41 EST

Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01)
Funding Opportunity PAR-15-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the PS-OPs is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming small transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.
Tue, 21 Oct 2014 01:47:51 EST

Brain Somatic Mosaicism and its Role in Psychiatric Disorders (Collaborative U01)
Funding Opportunity PAR-15-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites Cooperative Agreement (U01) applications from multi-disciplinary and synergistic teams of investigators proposing to identify and characterize the full spectrum of somatic variation in human brain samples and to assess the relationship of such variation with the pathophysiology of neuropsychiatric disorders. This FOA seeks to support applications exploring the extent of somatic variations across different brain regions in one or more psychiatric disorders using state-of-the-art genomic, computational, single-cell and other relevant approaches. Awards made under this FOA and the companion FOA (PAR-14-173) will be governed by a Brain Somatic Mosaicism (BSM) Network Steering Committee to accelerate scientific progress through the coordination of research strategies, analytical methods and data. The ultimate goal of this FOA and the companion FOA (PAR-14-173) is to address gaps in our understanding of the role of somatic genomic perturbations in the etiology of neuropsychiatric disorders. This FOA should be used when two or more collaborating sites are essential to complete the proposed research. It is required that the Research Strategy be identical across linked collaborative U01 applications, with the exception of a short section describing specific function of each application under "elements unique to that site." For a linked set of collaborative U01 applications, each application must have its own Program Directory/Principal Investigator (PD/PI) and the program must provide a mechanism for cross-site coordination, quality control, data and sample sharing among the BSM Network members as appropriate, database management, statistical analysis, and reporting.
Wed, 22 Oct 2014 09:51:46 EST